

( (S (NP-SBJ (NP Federal drug regulators)
             ,
             (ADJP concerned
		   (PP over
		       (NP British reports
			   (SBAR that
				 (S (NP-SBJ-1 diabetics)
				    (VP have
					(VP died
					    (PP-TMP after
						    (S-NOM (NP-SBJ *-1)
							   (VP shifting
							       (PP-CLR from
								       (ADJP animal))
							       (PP-CLR to
								       (NP human-based insulin))))))))))))
             ,)
     (VP say
         (SBAR 0
               (S (NP-SBJ they)
                  (VP are
                      (VP considering
                          (NP (NP a study)
                              (SBAR (WHNP-2 0)
				    (S (NP-SBJ *T*-2)
				       (VP to
					   (VP see
					       (SBAR if
						     (S (NP-SBJ similar deaths)
							(VP have
							    (VP occurred
								(ADVP-LOC here)))))))))))))))
     .))
( (S (NP-SBJ The United Kingdom reports)
     (VP came
         (PP-DIR from
		 (NP (NP Dr. Patrick Toseland)
		     ,
		     (NP (NP head)
			 (PP of
			     (NP clinical chemistry))
			 (PP-LOC at
				 (NP (NP (NP Guy 's)
					 Hospital)
				     (PP-LOC in
					     (NP London))))))))
     .))
( (S (PP-LOC In
	     (NP a telephone interview))
     (NP-TMP Friday)
     ,
     (NP-SBJ Dr. Toseland)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP the number)
			  (PP of
			      (NP (NP sudden , unexplained
				      deaths)
				  (PP of
				      (NP diabetics))))
                          (SBAR (WHNP-1 0)
                                (S (NP-SBJ he)
                                   (VP had
                                       (VP seen
                                           (NP *T*-1)
					   (NP-TMP this year))))))
                  (VP was
                      (NP-PRD (NP 17)
			      (PP compared
				  (PP with
				      (NP (NP just two)
					  (PP-TMP in
						  (NP 1985))))))))))
     .))
( (S (S-TPC-2 (NP-SBJ (NP (QP At least
			      six))
		      (PP of
			  (NP the deaths)))
	      (VP occurred
		  (PP-LOC among
			  (NP (NP (ADJP relatively young)
				  diabetics)
			      (SBAR (WHNP-1 who)
				    (S (NP-SBJ *T*-1)
				       (VP had
					   (VP switched
					       (PP-CLR from
						       (NP animal))
					       (PP-CLR to
						       (NP human insulin))
					       (PP-TMP within
						       (NP the past year))))))))))
     ,
     (NP-SBJ he)
     (VP said
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S (NP-SBJ (NP Dr. Solomon Sobel)
             ,
             (NP (NP director)
                 (PP of
                     (NP metabolism and endrocrine drug products))
                 (PP for
                     (NP the U.S. Food and Drug Administration)))
             ,)
     (VP said
         (SBAR 0
               (S (NP-SBJ FDA officials)
                  (VP have
                      (VP discussed
                          (NP (NP Dr. Toseland 's)
                              findings)
			  ``
			  (ADVP-MNR fairly intensively))))))
     .
     ''))
( (S (SBAR-ADV While
	       (S (NP-SBJ there)
		  (VP have
		      (VP been
			  (NP-PRD (NP no reports)
				  (PP of
				      (NP (NP similar sudden unexplained deaths)
					  (PP-LOC among
						  (NP (NP diabetics)
						      (PP-LOC in
							      (NP the U.S.)))))))))))
     ,
     (NP-SBJ Dr. Sobel)
     (VP said
         (SBAR 0
	       (S (NP-SBJ-1 the FDA)
		  (VP (VP plans
			  (S (NP-SBJ *-1)
			     (VP to
				 (VP examine
				     (NP (NP Dr. Toseland 's)
					 evidence)))))
		      and 
		      (VP is
			  (VP considering
			      (NP (NP its own study)
				  (ADVP-LOC here))))))))
     .))
( (S (NP-SBJ (NP Dr. Toseland)
             ,
             (NP a toxicologist)
             ,)
     (VP said
         (SBAR 0
               (S (NP-SBJ he)
                  (VP was
                      (VP preparing
                          (NP-2 an article)
			  (PP-CLR for
				  (NP a British forensic medical journal))
			  (S-ADV (NP-SBJ *-2)
				 (VP raising
				     (NP the possibility
					 (SBAR that
					       (S (NP-SBJ the deaths)
						  (VP may
						      (VP have
							  (VP occurred
							      (SBAR-TMP after
									(S (NP-SBJ human insulin)
									   (VP blunted
									       (NP (NP critical warning signs)
										   (VP indicating
										       (NP (NP (NP hypoglycemia)
											       ,
											       or
											       (NP low blood sugar)
											       ,)
											   (SBAR (WHNP-1 which)
												 (S (NP-SBJ *T*-1)
												    (VP can
													(VP kill
													    (NP diabetics))))))))))))))))))))))))
     .))
( (S (NP-SBJ (NP The usual warning signs)
             (PP of
                 (NP hypoglycemia)))
     (VP include
         (NP sweating
             ,
             anxiety and cramps))
     .))
( (S (PP With
         (NP proper warning))
     ,
     (NP-SBJ-1 diabetics)
     (VP can
	 (VP (ADVP-MNR easily)
	     raise
             (NP their blood sugar)
             (PP-CLR to
		     (NP safe levels))
             (PP-MNR by
		     (S-NOM (NP-SBJ *-1)
			    (VP eating
				(NP (NP sugar) or (NP sugary food)))))))
     .))
( (S ``
     (S-TPC-1 (NP-SBJ The anecdotal data)
	      (ADVP certainly)
	      (VP shows
		  (SBAR that
			(S (NP-SBJ (NP some)
				   (PP of
				       (NP the people)))
			   (VP were not
			       (ADJP-PRD aware
					 (PP of
					     (NP (NP the rapid onset)
						 (PP of
						     (NP hypoglycemia))))))))))
     , 
     ''
     (NP-SBJ Dr. Toseland)
     (VP said
	 (S *T*-1))
     .))
( (S (PP-LOC At
	     (NP (NP the U.S. National Institutes)
		 (PP of
		     (NP Health))))
     ,
     (NP-SBJ (NP Dr. Robert E. Silverman)
             ,
             (NP (NP chief)
                 (PP of
                     (NP the diabetes program branch)))
             ,)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP no evidence)
                          (PP of
                              (NP (NP unexpected deaths)
                                  (PP from
                                      (NP hypoglycemia)))))
                  (VP had
                      (VP shown
                          (PRT up)
                          (PP-LOC in
				  (NP (NP a study)
				      (PP of
					  (NP 1,500 diabetics))
				      (SBAR (WHNP-1 that)
					    (S (NP-SBJ *T*-1)
					       (VP has
						   (VP been
						       (PP-PRD under
							       (NP way))
						       (PP-LOC at
							       (NP NIH))
						       (PP-TMP for
							       (NP five years)))))))))))))
     .))
( (S (ADVP However)
     ,
     (NP-SBJ he)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP officials)
                          (VP conducting
                              (NP the study)))
                  (VP had n't
		      (VP been
			  (VP looking
			      (PP-CLR for
				      (NP (NP signs)
					  (PP of
					      (NP (NP problems)
						  (ADJP related
							(PP to
							    (NP hypoglycemia unawareness)))))))))))))
     .))
( (S ``
     (S-TPC-1 (NP-SBJ We)
	      (VP are
		  (ADVP-TMP now)
		  (VP monitoring
		      (PP-CLR for
			      (NP it))
		      (ADVP-MNR much more closely))))
     , 
     ''
     (NP-SBJ he)
     (VP said
	 (S *T*-1))
     .))
( (S ``
     (S-TPC-1 (NP-SBJ We)
	      (VP do
		  (VP know
		      (SBAR 0
			    (S (NP-SBJ there)
			       (VP are
				   (NP-PRD (NP slight differences)
					   (PP-LOC in
						   (NP (NP the way)
						       (SBAR (WHADVP-2 0)
							     (S (NP-SBJ (ADJP human and animal) insulins)
								(VP drive
								    (PRT down)
								    (NP blood sugar)
								    (ADVP-MNR *T*-2)))))))))))))
     , 
     ''
     (NP-SBJ Dr. Sobel)
     (VP said
	 (S *T*-1))
     .))
( (S (S-TPC-1 (NP-SBJ The human-based drug)
	      (VP (VP starts
		      (NP the blood sugar dropping)
		      (ADVP-TMP sooner))
		  and
		  (VP drives
		      (NP it)
		      (PRT down)
		      (ADVP-MNR faster))))
     ,
     (NP-SBJ he)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S ``
     (S-TPC-1 But
	      (NP-SBJ we)
	      (VP do n't
		  (VP believe
		      (SBAR 0
			    (S (NP-SBJ there)
			       (VP is
				   (ADJP-PRD enough
					     (PP of
						 (NP a difference))
					     (S (NP-SBJ *)
						(VP to
						    (VP be
							(ADJP-PRD clinically significant)))))))))))
     , 
     ''
     (NP-SBJ Dr. Sobel)
     (VP said
	 (S *T*-1))
     .))
( (S (NP-SBJ (NP Reports)
             (PP of
                 (NP (NP Dr. Toseland 's)
                     findings))
             (PP-LOC in
		     (NP the British press)))
     (VP have
         (VP triggered
             (NP widespread concern)
	     (PP-LOC among
		     (NP (NP diabetics)
			 (ADVP-LOC there)))))
     .))
( (S (NP-SBJ Both
             (NP the British Diabetic Association)
             and
             (NP (NP the Committee)
		 (PP on
		     (NP (NP Safety)
			 (PP-LOC in
				 (NP Medicines))))
                 (PRN --
		      (NP (NP (NP Britain 's)
			      equivalent)
			  (PP of
			      (NP the U.S. FDA)))
		      --)))
     (ADVP-TMP recently)
     (VP issued
         (NP (NP statements)
             (VP noting
                 (NP (NP the lack)
                     (PP of
                         (NP (NP hard scientific evidence)
                             (SBAR (WHNP-1 0)
				   (S (NP-SBJ *T*-1)
				      (VP to
					  (VP support
					      (NP (NP Dr. Toseland 's)
						  findings)))))))))))
     .))
( (S (PP-TMP On
	     (NP Friday))
     ,
     (NP-SBJ the American Diabetes Association)
     (VP issued
         (NP (NP a similar statement)
             (VP urging
                 (NP-1 the (QP six million) U.S. diabetics)
		 (S (NP-SBJ *-1)
		    not
		    (VP to
                        (VP overreact
                            (PP-CLR to
				    (NP the British report))))))))
     .))
( (S ``
     (S-TPC-2 (NP-SBJ (NP A loss)
		      (PP of
			  (NP (NP the warning symptoms)
			      (PP of
				  (NP hypoglycemia)))))
	      (VP is
		  (NP-PRD (NP a complex problem)
			  (SBAR (WHNP-1 that)
				(S (NP-SBJ-3 *T*-1)
				   (VP is
				       (ADJP-PRD very unlikely
						 (S (NP-SBJ *-3)
						    (VP to
							(VP be
							    (ADVP-PRD due
								      (PP (ADVP simply)
									  to
									  (NP (NP the type)
									      (PP of
										  (NP insulin))
									      (VP used
										  (NP *)))))))))))))))
     , 
     ''
     (NP-SBJ the American association)
     (VP said
	 (S *T*-2))
     .))
( (S (NP-SBJ The FDA)
     (ADVP-TMP already)
     (VP requires
	 (S (NP-SBJ drug manufacturers)
            (VP to
                (VP include
                    (NP warnings
			(SBAR *ICH*-1))
		    (PP-CLR with
			    (NP insulin products))
		    (SBAR-1 that
			    (S (NP-SBJ (NP symptoms)
				       (PP of
					   (NP hypoglycemia)))
			       (VP are
				   (ADJP-PRD (ADJP less pronounced)
					     (PP with
						 (NP human insulin))
					     (PP than
						 (PP with
						     (NP animal-based products)))))))))))
     .))
( (S (NP-SBJ (NP Eli Lilly & Co.)
             ,
             (NP the Indianapolis-based drug manufacturer)
             ,)
     (VP dominates
         (NP the U.S. human insulin market)
         (PP with
             (NP (NP its product)
                 (VP known
                     (NP *)
                     (PP-CLR as
			     (NP Humulin))))))
     .))
( (S (NP-SBJ Lilly)
     (VP is
         (VP building
             (NP (NP plants)
		 (SBAR (WHADVP-1 0)
		       (S (NP-SBJ *)
			  (VP to
			      (VP make
				  (NP the insulin)
				  (ADVP-LOC *T*-1))))))
	     (PP-LOC in
		     (NP (NP Indianapolis)
			 and
			 (NP (NP Fagershein)
			     ,
			     (NP-LOC France))))))
     .))
( (S (PP-LOC In
	     (NP its latest annual report))
     ,
     (NP-SBJ Lilly)
     (VP said
         (SBAR 0
               (S (NP-SBJ Humulin sales)
                  (VP have
                      (VP shown 
			  ``
                          (NP excellent growth))))))
     .
     ''))
( (S (NP-SBJ Lilly officials)
     (VP (VP said
             (SBAR 0
                   (S (NP-SBJ they)
                      (VP had
                          (VP seen
                              (NP (NP reports)
                                  (PP of
                                      (NP (NP hypoglycemic unawareness)
					  (PP-LOC among
						  (NP (NP some patients)
						      (VP making
							  (NP (NP the shift)
							      (PP from
								  (ADJP animal))
							      (PP to
								  (NP human insulin))))))))))))))
         , 
	 but 
	 (VP did n't
	     (VP know
		 (SBAR if
		       (S (NP-SBJ the problem)
			  (VP had
			      (VP caused
				  (NP any deaths))))))))
     .))
( (S (NP-SBJ (NP Dr. Leigh Thompson)
             ,
             (NP a Lilly group vice president)
             ,)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP (NP the company 's)
			      clinical trials)
                          (PP of
                              (NP both its 
				  (ADJP animal and human-based)
				  insulins)))
                  (VP indicated
                      (NP (NP no difference)
			  (PP-LOC in
				  (NP (NP the level)
				      (PP of
					  (NP hypoglycemia))))
			  (PP-LOC between
				  (NP (NP users)
				      (PP of
					  (NP either product)))))))))
     .))
( (S (NP-SBJ Dr. Toseland)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP most)
			  (PP of
			      (NP the British diabetics))
                          (SBAR (WHNP-1 who)
                                (S (NP-SBJ *T*-1)
                                   (VP died))))
                  (VP had
		      (VP been
			  (VP taking
			      (NP (NP a human-based insulin)
				  (VP made
				      (NP *)
				      (PP by
					  (NP-LGS (NP Novo/Nordisk)
						  ,
						  (NP a Danish manufacturer)))))))))))
     .))
( (S (NP-SBJ (NP None)
             (PP of
                 (NP the diabetics)))
     (VP were
         (VP using
             (NP (NP Lilly 's)
                 insulin)))
     .))
